CD200R1 and neoplasm: Note that aggressive tumor growth led to WT control mice having to be sacrificed within 18 d or 21 d of surgery (panels a/b), unlike immunotherapy-treated mice receiving anti-CD200R (panel b) where mice were able to be followed for ≥90 d post surgery.